A male with metastatic colon adenocarcinoma treated at 210 mg has SD and continues full-dose therapy beyond fourteen cycles; he had six prior lines of chemotherapy for metastatic disease, (including flurouracil, oxaliplatin, bevacizumab, irinotecan, panitumumab, anti PD-1 monoclonal antibodies, and an investigational SIRPα antagonist) and has both an ongoing 13% reduction in sum of longest dimensions of the target lesions, and showed a parallel 48% reduction in serum carcinoembryonic antigen (CEA) level. This evidence concerns the gene SIRPA and metastatic neoplasm.